Dilemma in diagnosis and management of rare primary pleural Ewing’s sarcoma with synchronous limited metastatic disease

2021 ◽  
Vol 14 (6) ◽  
pp. e243495
Author(s):  
Abhijith Bhaskaran ◽  
Pooja Sethi ◽  
Pampa Ch Toi ◽  
Prasanth Penumadu

We present a case of a 34-year-old woman who presented with complaints of fever, cough and dyspnoea of 2 months’ duration. On evaluation, she was diagnosed with a rare entity primary pleural Ewing’s sarcoma with synchronous metastases to mediastinal, supraclavicular nodes and single vertebra. Due to the rarity of this entity and lack of treatment guidelines on extraosseous Ewing’s sarcoma, the patient was managed with a combination of multiagent chemotherapy, surgery and radiotherapy as per standard guidelines for skeletal Ewing’s sarcoma. We present this case to discuss differential diagnoses and management dilemmas encountered on the use of local modalities such as surgery and radiotherapy for control of primary and metastatic sites.

2018 ◽  
Vol 39 (3) ◽  
pp. 380 ◽  
Author(s):  
LakshmiKeerthana Killampalli ◽  
ARavi Prakash ◽  
AVikram Simha Reddy ◽  
M Rajinikanth

1997 ◽  
Vol 15 (2) ◽  
pp. 574-582 ◽  
Author(s):  
R B Raney ◽  
L Asmar ◽  
W A Newton ◽  
C Bagwell ◽  
J C Breneman ◽  
...  

PURPOSE One hundred thirty of 2,792 patients (5%) registered on three Intergroup Rhabdomyosarcoma Study clinical trials (IRS-I, -II, and -III) from 1972 to 1991 had an extraosseous Ewing's sarcoma (EOE). We report here the results of multimodality therapy for this tumor. PATIENTS AND METHODS The 130 patients were less than 21 years of age; 70 (54%) were males. Primary tumor sites were on the trunk in 41 patients, an extremity in 34, the head/neck in 23, the retroperitoneum/pelvis in 21, and other sites in 11. One hundred fourteen patients had no metastases at diagnosis. In 21 patients, the tumor was completely resected; in 30, the localized or regional tumor was grossly resected, and in 63 patients, grossly visible sarcoma was left behind. Sixteen patients (12%) had distant metastases at diagnosis. All patients were given multiagent chemotherapy and most received irradiation (XRT); none were treated with bone marrow transplantation. RESULTS One hundred seven patients (82%) achieved a complete response. At 10 years, 62%, 61%, and 77% of the patients were alive after treatment on IRS-I, IRS-II, or IRS-III therapeutic protocols, respectively, similar to figures obtained in all IRS patients. At last follow-up evaluation, 42 patients had died of progressive tumor and one of infection. Survival at 10 years was most likely for patients with tumor that arose in the head and neck, extremities, and trunk, and for those who underwent grossly complete tumor removal before initiation of chemotherapy. For patients with localized, gross residual tumor, adding doxorubicin (DOX) to the combination of vincristine, dactinomycin, cyclophosphamide (VAC), and XRT did not significantly improve survival in 39 patients (62% alive at 10 years) compared with that of 24 patients treated with VAC and XRT without DOX (65% alive at 10 years, P = .93). CONCLUSION This series indicated that EOE in children is similar to rhabdomyosarcoma (RMS) in its response to multimodal treatment. No benefit was apparent from the addition of DOX to VAC chemotherapy in patients with gross residual EOE.


2019 ◽  
Vol 12 (10) ◽  
pp. e230768
Author(s):  
Jeewan Ram Vishnoi ◽  
Vijay Kumar ◽  
Kirti Srivastava ◽  
Sanjeev Misra

Ewing’s sarcoma (ES) is the second most common malignant primary bone tumour in children and adolescents. It primarily affects the diaphysis of long bones and pelvis. ES arising from temporal bone is extremely rare. To date, 43 such cases have been described in the literature. Clinical and radiological features are non-specific. Diagnosis is based mainly on immunohistochemistry. The present article presents an extremely rare case of ES of the temporal bone in a 20-year young man, and he was successfully treated with multiagent chemotherapy and radiotherapy.


Author(s):  
Alan Alexander ◽  
Kyle Hunter ◽  
Michael Rubin ◽  
Ambarish P. Bhat

AbstractExtraosseous Ewing’s sarcoma (EES), first described in 1969, is a malignant mesenchymal tumor just like its intraosseous counterpart. Although Ewing’s sarcomas are common bone tumors in young children, EESs are rarer and more commonly found in older children/adults, often carrying a poorer prognosis. We discuss the multimodality imaging features of EES and the differential diagnosis of an aggressive appearing mass in proximity to skeletal structures, with pathologic correlates. This review highlights the need to recognize the variability of radiologic findings in EES such as the presence of hemorrhage, rich vascularity, and cystic or necrotic regions and its imaging similarity to other neoplasms that are closely related pathologically.


2014 ◽  
Vol 21 (11) ◽  
pp. 1183-1184 ◽  
Author(s):  
Yutaka Yamamoto ◽  
Masahiro Nozawa ◽  
Nobutaka Shimizu ◽  
Takafumi Minami ◽  
Kazuhiro Yoshimura ◽  
...  

2018 ◽  
Vol 35 (3) ◽  
pp. 541-545
Author(s):  
Amir Humza Sohail ◽  
Mohammed Sachal ◽  
Muhammad Arslan Arif Maan ◽  
Muhammad Soban ◽  
Muhammad Salman Khan ◽  
...  

Author(s):  
Ankur Gupta ◽  
Ancy S. Sofia ◽  
Kanwar Sen

<p class="abstract">Extra skeletal Ewing’s sarcoma (EES) is a rare, rapidly growing, round cell malignant tumour that can develop in the soft tissue at any location. Involvement of the paranasal sinus is a very rare entity. Nearly 80% of patients are younger than 20 years. Diagnosis is made after histopathological examination, immunohistochemical studies and cytogenetic studies. Treatment includes a multidisciplinary approach with surgery as the first line followed by chemotherapy and radiotherapy.</p><p class="abstract"> </p>


2013 ◽  
Vol 42 (11) ◽  
pp. 1002-1005 ◽  
Author(s):  
Mitsuaki Ishida ◽  
Muneo Iwai ◽  
Keiko Yoshida ◽  
Akiko Kagotani ◽  
Hidetoshi Okabe

Sign in / Sign up

Export Citation Format

Share Document